Drawing for TEZDUVI

USPTO serial 88182287

TEZDUVI

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BUSH, KAREN K
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TEZDUVI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Timothy J. Gaul

Timothy J. Gaul Amgen Inc.One Amgen Center DriveTrademark Operations MS-28-5-AThousand Oaks, CA 91320-1799

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the blood, skin, bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 7, 2021MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 7, 2021ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 31, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 29, 2020EX2GSOU EXTENSION 2 GRANTED—
Oct 29, 2020EXT2SOU EXTENSION 2 FILED—
Oct 29, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 30, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 28, 2020EX1GSOU EXTENSION 1 GRANTED—
Apr 28, 2020EXT1SOU EXTENSION 1 FILED—
Apr 28, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 5, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 10, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 10, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 21, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 8, 2019ALIEASSIGNED TO LIE—
Jul 29, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 25, 2019XAECEXAMINER'S AMENDMENT ENTERED—
Jul 25, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 25, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 25, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 7, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 7, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 13, 2018GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 13, 2018GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 13, 2018CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Dec 11, 2018DOCKASSIGNED TO EXAMINER—
Nov 20, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 8, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance